Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

Rhea-AI Summary

Avalyn (NYSE:AVLN) announced April 27, 2026 the appointments of Adam Golden as General Counsel and Head of Business Development and Frank Salisbury as Senior Vice President, Commercial.

Adam Golden brings over 30 years of legal and business development experience including senior roles at Freshfields, Hogan Lovells, and Kaye Scholer. Frank Salisbury brings 24+ years of commercial leadership and prior launches of therapies including ESBRIET and WINREVAIR. The hires target clinical advancement and commercial readiness ahead of future commercialization.

Positive

• Appointed Adam Golden as General Counsel and Head of BD
• Appointed Frank Salisbury as Senior VP, Commercial
• Management hires strengthen commercial and legal expertise pre-commercialization
• Frank Salisbury led U.S. launch of ESBRIET (pirfenidone)

Negative

• No financial metrics or guidance provided with appointments

Key Figures

Golden experience: over three decades Golden experience (years): over 30 years Two decades tenure: over two decades +2 more

5 metrics

Golden experience over three decades Advising biopharma companies

Golden experience (years) over 30 years Legal, business development, corporate strategy

Two decades tenure over two decades Career at Kaye Scholer

Salisbury experience more than 24 years Commercial leadership in biotech and pharma

Shares float 11,800,000 shares Shares float from risk context

Market Reality Check

Price: $27.36

normal vol

$27.36 Last Close

Market Pulse Summary

This announcement focuses on strengthening Avalyn’s leadership as it advances clinical programs and ...

Analysis

This announcement focuses on strengthening Avalyn’s leadership as it advances clinical programs and prepares for future commercialization. The appointments bring over 30 years of legal and strategic experience and more than 24 years of commercial leadership in rare respiratory diseases. With no recent news history or sector moves provided, context centers on execution: investors may watch how this team supports clinical progress, regulatory interactions, and eventual commercialization efforts for serious respiratory conditions.

Key Terms

idiopathic pulmonary fibrosis, ipf, pulmonary arterial hypertension, pah, +2 more

6 terms

idiopathic pulmonary fibrosis medical

"including ESBRIET® (pirfenidone) for idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

ipf medical

"including ESBRIET® (pirfenidone) for idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.

pulmonary arterial hypertension medical

"WINREVAIR® for pulmonary arterial hypertension (PAH)"

Pulmonary arterial hypertension is a progressive medical condition in which the arteries that carry blood from the heart to the lungs become narrowed or stiff, causing high pressure in the lung circulation and extra strain on the heart — like a pump working against clogged pipes. For investors, it matters because the condition defines the need, market size, clinical trial design, regulatory hurdles and potential revenue or risk for companies developing drugs, devices or diagnostics to treat or manage it.

pah medical

"sotatercept for PAH. Their expertise strengthens"

Pulmonary arterial hypertension (PAH) is a chronic condition in which the small blood vessels that carry blood from the heart to the lungs become narrowed or stiff, raising pressure and forcing the heart to work harder—like trying to squeeze water through a narrowed garden hose. It matters to investors because drug development, clinical trial outcomes, regulatory approvals and pricing decisions for PAH therapies can create significant revenue opportunities or financial risks for biotech and pharmaceutical companies operating in this therapeutic area.

sec compliance regulatory

"mergers and acquisitions, strategic collaborations, corporate governance, and SEC compliance."

SEC compliance means that a public company follows the rules and disclosure requirements set by the U.S. Securities and Exchange Commission, including accurate financial reporting, timely filings, and truthful public statements. For investors, it matters because these rules act like safety rails and a clear mirror: they help ensure companies provide reliable information, reduce the chance of fraud or surprises, and make it easier to compare and trust different investments.

fda-approved therapies regulatory

"an established leader in launching multiple FDA-approved therapies, including ESBRIET"

FDA-approved therapies are medical treatments that the U.S. Food and Drug Administration has formally reviewed and authorized for specific uses after finding sufficient evidence of safety and effectiveness. For investors, approval is like a business license and safety inspection rolled into one: it clears the main regulatory hurdle to sell the product widely, reduces development uncertainty, and can unlock insurance coverage and predictable revenue streams.

AI-generated analysis. Not financial advice.

BOSTON, April 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm for serious, rare respiratory diseases, today announced two appointments that further strengthen its leadership team as the company advances its clinical programs and prepares for future commercialization. Adam Golden, a seasoned legal and business adviser with over three decades of experience advising biopharma companies, was appointed General Counsel and Head of Business Development. Frank Salisbury, an established leader in launching multiple FDA-approved therapies, including ESBRIET^® (pirfenidone) for idiopathic pulmonary fibrosis (IPF), was appointed Senior Vice President, Commercial.

“We are thrilled to welcome Adam and Frank to Avalyn at this important stage in our evolution,” said Lyn Baranowski, Chief Executive Officer of Avalyn. “Adam brings deep legal experience guiding life sciences companies through critical inflection points involving business development and legal strategy, all of which will be invaluable as we transition to life as a public company. Frank has a proven track record of building and leading commercial organizations for innovative respiratory treatments, including oral pirfenidone for IPF and sotatercept for PAH. Their expertise strengthens our ability to execute across corporate strategy, business operations, and commercial readiness as we advance our pipeline and position Avalyn for long-term success.”

Adam Golden has over 30 years of experience advising biopharma companies, spanning legal, business development, and corporate strategy. Prior to joining Avalyn, Mr. Golden was a Partner and Global Head of Life Sciences at Freshfields LLP, where he founded and led the build-out of an internationally recognized life sciences practice. Previously, he served as Partner and Head of the New York Corporate Practice Group at Hogan Lovells, and spent over two decades at Kaye Scholer, where he held multiple roles, including Partner and Co-Chair, Corporate Department. Over the course of his career, Mr. Golden has advised on mergers and acquisitions, strategic collaborations, corporate governance, and SEC compliance. He currently serves on the Board of Advisors for Life Science Cares. Mr. Golden holds a J.D. from New York University School of Law and an A.B. in Chemistry from Princeton University. 

Frank Salisbury brings more than 24 years of commercial leadership experience across biotechnology and large pharmaceutical companies, with a focus on rare respiratory diseases. Over the course of his career, he has played a key role in the launch and commercialization of multiple therapies. At InterMune/Genentech, he led the U.S. launch and served as National Head of Sales for ESBRIET^® (pirfenidone) in IPF. He also held senior commercial roles at Acceleron Pharma, where he supported the launch of WINREVAIR^® for pulmonary arterial hypertension (PAH), as well as at Actelion, where he played a core role in the commercialization of OPSUMIT^® (macitentan) for PAH. He joins Avalyn from PureTech Health, where he was the Senior Vice President for Commercial and Product Strategy. Mr. Salisbury earned a B.A. in International Relations and an M.B.A. from Stanford University, and was a Fulbright Scholar in Germany, where he studied HIV prevention interventions. 

About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging tolerability and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone data. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver dual antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.

Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com

Media Contact:
Kat Lippincott, Deerfield Group
kat.lippincott@deerfieldgroup.com
media@avalynpharma.com

FAQ

Who did Avalyn (AVLN) appoint as General Counsel and Head of Business Development on April 27, 2026?

Adam Golden was appointed General Counsel and Head of Business Development. According to Avalyn, he brings over 30 years advising biopharma companies and senior roles at Freshfields, Hogan Lovells, and Kaye Scholer.

What is Frank Salisbury's role at Avalyn (AVLN) and what experience does he bring?

Frank Salisbury was named Senior Vice President, Commercial. According to Avalyn, he has 24+ years in commercial leadership and helped launch therapies including ESBRIET and WINREVAIR.

How do the April 27, 2026 Avalyn (AVLN) hires support the company’s strategy?

The hires bolster legal, business development, and commercial readiness ahead of commercialization. According to Avalyn, both executives strengthen corporate strategy and go-to-market preparation for the pipeline.

Did Avalyn (AVLN) disclose financial guidance or targets with these appointments?

No, Avalyn did not disclose financial guidance or targets alongside the appointments. According to Avalyn, the announcement focused on leadership experience and commercial/legal capabilities.

What past launches does Avalyn cite for Frank Salisbury relevant to AVLN commercialization?

Avalyn cites Salisbury’s role in launching ESBRIET (pirfenidone) for IPF and supporting WINREVAIR for PAH. According to Avalyn, these launches reflect his rare respiratory commercialization experience.